Deyuan Pharmaceuticals: Net profit of 237 million yuan in 2025, a year-on-year increase of 33.87%

Deyuan Pharmaceutical releases its performance brief, achieving operating revenue of 1.058 billion yuan in 2025, a year-on-year increase of 21.80%; net profit of 237 million yuan, a year-on-year increase of 33.87%. The main reasons for the company’s growth in operating performance during the reporting period are: the company has always adhered to a marketing-first business philosophy, continuously strengthened its sales foundation, fully promoted market expansion, and achieved steady growth in the sales volume of products on sale. Among them, the sales of “Furuitong” and “Bokaiqing” maintained steady increases, laying a solid foundation for the company’s revenue growth; products such as Cangrelor tablets, Empagliflozin tablets, and Metformin-empagliflozin tablets (III) experienced rapid sales growth, while newly approved products like Ibrutinib tablets and Febuxostat tablets further promoted steady improvement in operating performance; products such as Linagliptin tablets (5mg), Sitagliptin Metformin tablets (II) (50mg/850mg), and Sitagliptin phosphate tablets (100mg) won bids in the tenth batch of centralized drug procurement, with shipments starting from March 2025 to relevant bidding regions, driving rapid sales growth; the company continues to strengthen internal operational management, optimize personnel structure, strictly control costs, reduce expenses, and improve overall profitability and operational quality.